Because of this evidence for an important role of CD4 + T cells in HCMV disease we investigated the development of HCMV-specific T cell proliferation after allogeneic Thirty patients undergoing allogeneic BMT were screened post-transplant together with their marrow BMT and its correlation with the occurrence of HCMV disease early (during the first 100 days) and late (Ͼ100 days) donors for CMV-specific T cell proliferation and the occurrence of CMV disease. Twenty-one of these post-transplant. As shown in several studies, long-term use of prophylacpatients received a marrow transplant from an HLAmatched sibling donor, and nine from an HLA-matched tic ganciclovir, 7 or use in a pre-emptive setting 8 is associated with a low rate of early-, but an increased incidence of unrelated donor. All these patients were either CMV seropositive and/or had received a transplant from a late-onset, HCMV disease. Since ganciclovir has been shown to exhibit myelo-and immunosuppressive proper-CMV-seropositive donor. Patients were monitored for CMV-viraemia until day +100 post-BMT by PCR and ties 7,9 long-term use was shown to delay recovery of the HCMV-specific immune reconstitution post-transplant. In virus culture, and thereafter by virus culture only when clinically indicated. The proliferative T cell response spite of ganciclovir prophylaxis in patients receiving a transplant from an HLA-matched unrelated donor (MUD) was investigated at regular monthly intervals beginning on day +30. A proliferative response to HCMV (median, an increased rate of HCMV infection and disease has been documented. 10 We were thus specifically interested in evalday +123) was documented in these patients between day +37 and +730 post-BMT. None of the patients with uating HCMV-specific immune reconstitution in this patient cohort. a documented CMV-specific T cell proliferation on day 120 (n = 17) developed CMV disease in the later postWe used a HCMV-specific proliferation assay to screen patients at regular monthly intervals until at least 1 year transplant period, but of the patients lacking CMVspecific proliferation (n = 13), 30.8% developed CMV post-BMT. We were specifically interested in identifying patients at risk of developing late-onset HCMV disease by disease after day 120. Thus, patients lacking a CMVspecific T-helper cell response might benefit from differentiating cases according to delayed kinetics of HCMV-specific T cell reconstitution after transplantation sensitive screening for CMV infection and pre-emptive therapy after day +100.
Summary:
Because of this evidence for an important role of CD4 + T cells in HCMV disease we investigated the development of HCMV-specific T cell proliferation after allogeneic Thirty patients undergoing allogeneic BMT were screened post-transplant together with their marrow BMT and its correlation with the occurrence of HCMV disease early (during the first 100 days) and late (Ͼ100 days) donors for CMV-specific T cell proliferation and the occurrence of CMV disease. Twenty-one of these post-transplant.
As shown in several studies, long-term use of prophylacpatients received a marrow transplant from an HLAmatched sibling donor, and nine from an HLA-matched tic ganciclovir, 7 or use in a pre-emptive setting 8 is associated with a low rate of early-, but an increased incidence of unrelated donor. All these patients were either CMV seropositive and/or had received a transplant from a late-onset, HCMV disease. Since ganciclovir has been shown to exhibit myelo-and immunosuppressive proper-CMV-seropositive donor. Patients were monitored for CMV-viraemia until day +100 post-BMT by PCR and ties 7,9 long-term use was shown to delay recovery of the HCMV-specific immune reconstitution post-transplant. In virus culture, and thereafter by virus culture only when clinically indicated. The proliferative T cell response spite of ganciclovir prophylaxis in patients receiving a transplant from an HLA-matched unrelated donor (MUD) was investigated at regular monthly intervals beginning on day +30. A proliferative response to HCMV (median, an increased rate of HCMV infection and disease has been documented. 10 We were thus specifically interested in evalday +123) was documented in these patients between day +37 and +730 post-BMT. None of the patients with uating HCMV-specific immune reconstitution in this patient cohort. a documented CMV-specific T cell proliferation on day 120 (n = 17) developed CMV disease in the later postWe used a HCMV-specific proliferation assay to screen patients at regular monthly intervals until at least 1 year transplant period, but of the patients lacking CMVspecific proliferation (n = 13), 30.8% developed CMV post-BMT. We were specifically interested in identifying patients at risk of developing late-onset HCMV disease by disease after day 120. Thus, patients lacking a CMVspecific T-helper cell response might benefit from differentiating cases according to delayed kinetics of HCMV-specific T cell reconstitution after transplantation sensitive screening for CMV infection and pre-emptive therapy after day +100.
either from an HLA-identical sibling or from an unrelated bone marrow donor. Keywords: CMV infection; T cell proliferation; late onset CMV disease
Materials and methods

Patients
Human cytomegalovirus is still a major cause of morbidity and mortality in recipients of an allogeneic stem cell transThirty consecutive allogeneic bone marrow transplant plant. Cell-mediated immunity has been shown to be of recipients at risk of developing HCMV infection post-transimportance in the host response to cytomegalovirus infecplant (patient and/or donor HCMV-seropositive) were tion.
1,2 Recovery from HCMV disease and effective control screened monthly for recovery of HCMV-specific T cell of HCMV infection correlates with cellular immune proliferation. Patient characteristics are shown in Table 1 . responses against HCMV. 3, 4 In patients recovering from The serostatus of patients, bone marrow donors, and blood HCMV disease a significant increase in the lymphocyte donors was determined by an enzyme-linked immunosorbcounts can be documented in contrast to patients failing ent assay (ELISA) technique. All HCMV-seropositive antiviral therapy who were found to maintain low lymphopatients or patients who had received a transplant from a cyte counts.
5,6 Persistent CD4 + lymphocytopenia was found HCMV-seropositive marrow donor received blood products to be a particularly bad prognostic factor for patients with unscreened for HCMV. Oral acyclovir was administered to HCMV infection and disease. 5 all patients at a dosage of 4 × 400 mg/day for prophylaxis of herpes simplex infections, until day +100 after BMT. All patients received oral antibiotic and oral antifungal conazol, 400 mg/day from day −7 until day +50 after BMT. HCMV-antigen preparation HCMV infection HCMV antigen was prepared as described previously.
14 Briefly, human foreskin fibroblasts (HFF) infected with HCMV infection was determined by either two consecutive HCMV AD169 were grown until they showed a cytopathic PCR-positive blood samples or by a positive culture from effect of 90%. The infected cells were trypsinized, washed blood samples, urine or throat washings. In all patients in twice with glycine-buffered saline (0.15 m, pH 8.5), sonthis study, treatment was started on the second consecutive icated in 0.5 m glycine-buffered saline pH 8.5 (140 W, 3 PCR-positive blood sample. HCMV disease was diagnosed min) and extracted overnight. After centrifugation at 4°C according to the criteria defined by the Fourth International (500 g, 15 min) the supernatants were aliquoted and stored Cytomegalovirus Workshop in Paris 11 as follows: HCMV at −70°C. Cell lysates from uninfected HFF as negative pneumonia: dyspnoea, interstitial infiltrates on the chest controls were obtained as described for the infected HFF. radiograph, positive HCMV culture of bronchial washings;
As an alternative HCMV-specific antigen preparation, the HCMV enteritis: gastrointestinal symptoms, demonstration supernatants of infected cells were centrifuged and the disof HCMV by histology or immunohistology; HCMV hepasolved pellets (mainly virions) used as comparison with the titis: abnormal liver function, typical histologic changes and glycine-extracted antigen of the infected cells. The two detection of HCMV in the liver biopsy by culture or HCMV antigen preparations and the respective negative DNA hybridization.
controls were tested in a proliferation assay of PBMC obtained from HCMV-seropositive and HCMV-seroneg-
HCMV-PCR
ative healthy donors at different dilutions, to define the optimum concentration of antigen for T cell proliferation The HCMV-PCR was performed as previously induction. described.
12,13 Briefly, a 147 bp fragment from the fourth exon of the immediate-early gene was amplified from DNA of PBMC in 32 cycles. The PCR product was blotted onto Proliferation assay a nylon membrane and hybridised with an internal DIGProliferation assays were performed by stimulation of 10 5 dUTP-labelled (Boehringer Mannheim, Mannheim, PBMC per well with an optimum concentration of the glyGermany) HCMV-specific oligonucleotide. Detection of cine-extracted HCMV-antigen, of the virions and negative the hybridisation product was performed by anti-DIG-percontrol antigen from uninfected HFF. As positive controls, oxidase-labelled antibody and chloronapthol as substrate PHA and IL-2 stimulation were included. Moreover, a samfor the peroxidase reaction.
ple from a healthy donor was tested in every assay to confirm proliferation conditions. Every sample investigated Treatment of HCMV infection showed proliferation to PHA and IL-2. The assay was performed for only 3 days to avoid in vitro stimulation of the PCR monitoring of blood samples and viral cultures from naive T cell response. After 3 days, 1 Ci 3 H-thymidine blood, throat washings and urine was performed weekly was added for 16 h and the cultures harvested onto glass starting on day 0 until day +100 after BMT. Patients fiber filter paper with a multiple automated sample harreceived pre-emptive antiviral therapy with ganciclovir in vester. The filter paper was dried and processed for liquid a dosage of 2 × 5 mg/kg body weight per day for 2 weeks scintillation counting. at the time of the second consecutive positive PCR signal. HCMV hyperimmunoglobulin, 0.2 g/kg body weight, was additionally given to patients with HCMV-induced interPresentation of data and statistical analysis stitial pneumonia or enteritis on day 1, 3, 5, 7 and 10 until signs and symptoms of HCMV disease had disappeared.
The incremental cellular response was defined as the median counts per minute (c.p.m.) from triplicate wells. All other manifestations of HCMV disease were treated with ganciclovir 2 × 5 mg/kg body weight for at least 14
Results are expressed as the stimulation index: healthy marrow donors as well as the HCMV seronegative patients receiving a transplant from a HCMV-seronegative Only proliferative responses corresponding to a stimulation donor and blood products from HCMV-seronegative blood index Ͼ3 were considered as a positive result (Figure 1) . donors, lacked proliferation to the different HCMV antiThe P values were evaluated according to the 2 test. gens (range 0.6-2.3; median, 1.0) (Figure 1) .
Results
HCMV-specific T cell proliferation post-BMT
Reconstitution of a proliferative response to HCMV post-HCMV-specific T cell proliferation in control subjects or BMT could be documented in 25 of the 30 patients anabefore BMT lysed. It showed a considerable variation in strength with Reproducible assessment of proliferative HCMV-specific T time limits ranging from day 37 to day 730 post-BMT. cell responses was obtained by stimulation of PBMC with Nineteen of 20 HCMV-PCR positive patients showed no HCMV antigen from infected HFF diluted 1:200. Incuproliferative response to HCMV during early viraemia bation for 3 days, in contrast to 7 days used in most pre-(prior to day +100). An example of a representative patient vious assays, was sufficient to detect HCMV-specific T cell with a detectable HCMV-specific proliferative response proliferation in all healthy seropositive individuals. The after early viraemia is shown in Figure 2 . The patient with glycine-extracted HCMV antigen but not the virion prepa documented proliferative response to HCMV during viraaration was found to reproducibly induce proliferative emia did not receive antiviral therapy in spite of a recurresponses in repeated blood samples of all seropositive rence of HCMV-DNaemia after day +100 and successfully healthy individuals tested (Figure 1 ). All seropositive but controlled HCMV infection without showing any clinical none of the seronegative healthy marrow donors showed a signs and symptoms of HCMV disease. stimulation index Ͼ3 (range 3.7-37.7; median, 9.9) with All patients without cGVHD (n = 13) after day +100 post-grafting developed proliferative T cell responses to HCMV at a median of 91 days (range 37-204 days) after BMT. In contrast, five (3/5 patients transplanted from a MUD) of 17 patients with cGVHD did not develop a proliferative T cell response until 1 year post-BMT. Thus, in patients with cGVHD (Table 2) the reconstitution of the proliferative T cell response to HCMV antigen was markedly delayed (P = 0.01 for day 120 post-BMT).
The kinetics of reconstitution of HCMV-specific T cell proliferation appeared to be independent of the HCMV serostatus of the donor. The median day of development of a proliferative response to HCMV post-BMT was similar in patients with a seropositive (day 115, n = 22) or seronegative marrow donor (day 118, n = 8) at least in this small patient population. CMV-specific lymphocyte proliferation was documented on day +120 in all six patients who remained PCR-and culture-negative throughout the whole post-transplant period until day +100. A comparison of This follow-up study of 30 patients following allogeneic BMT for up to more than 1 year post-grafting presents a clear correlation between the recovery of the HCMV-spepatients receiving either a graft from an HLA-identical sibcific lymphoproliferative T cell responses and the clinical ling or from a matched unrelated donor is shown in outcome of HCMV infection and reactivation. None of Figure 3 . The patient group receiving a marrow transplant the patients with a documented proliferative response from an unrelated donor showed significantly delayed celludeveloped HCMV-disease later on in the post-transplant lar immune responses to HCMV in comparison to patients period. In contrast, patients lacking a proliferative response receiving a transplant from an HLA-identical sibling donor after day 120 post-BMT still carried a risk of at least 31% (P = 0.05 for day 200 post-BMT, no significance for day of developing HCMV disease in the later post-transplant 120 post-BMT). Three of the nine patients transplanted period. Thus, the proliferation assay can be used to identify from a MUD developed no stimulatory activity to HCMV patients at risk of developing late-onset HCMV disease. antigen until they died (day 160, 435 and 589 post-BMT)
The lymphocyte stimulation assay with HCMV antigen in contrast to two of 21 patients transplanted from a sibling in vitro was shown to be mostly T helper cell mediated.
4,15
donor (death on day 210 and day 365 post-BMT). We found the HCMV antigen preparation to be of imporNo patient with an HCMV-specific proliferative T cell tance to obtain reliable results. Whereas some groups have response developed HCMV disease in the later post-transused highly purified virions, 15,16 others separated nuclear plant period (P = 0.01) irrespective of having been grafted antigen and membrane antigen 3 or used crude HCMV antifrom an unrelated or sibling donor, whereas 30.8% of gen by lysing the infected fibroblasts. 17, 18 We used glycinepatients (4/13) lacking a proliferative response to HCMV, extracted HCMV antigen from lysed infected fibroblasts as developed disease. One patient transplanted from an unrereported 4,14,19 and obtained HCMV-specific T cell proliferlated donor developed fatal HCMV pneumonia 8 months ation in all seropositive healthy persons tested. None of the post-BMT when still lacking HCMV-specific T cell seronegative controls showed a positive result (Figure 1 ). Whereas Li et al 7 found a stimulation factor of 1.9 to be sufficient for a positive result we set our index to 3.
As already reported by Meyers et al 1 and Quinnan et al,
2
T cells play an important role in controlling HCMV infection and disease. HCMV-specific CD8 + T cells were shown to be protective in mice 20 and humans. 21 The importance of HCMV-specific CD4 + T cells was reported by other authors. Reconstitution of CD8 + T cells specific for HCMV was reported to correlate with prior or concurrent recovery of CD4 + HCMV-specific T H responses. 22 In recipients of solid organ transplants, lymphoproliferative responses to HCMV after transplantation were found to protect from HCMV disease in spite of HCMV reactivation. 23 Ljungman et al 24 also found a correlation between the lack of T helper cell proliferation capacity and the occurrence of IP post-BMT. In patients with other types of symptomatic HCMV diseases the development of a virus-specific proliferative response was associated with a good clinical outcome. The lack of recovery or a progressive decline of CD4 + T cells HCMV infection.
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HCMV-seropositive recipients of an autologous stem cell transplant showed HCMV-specific T cell proliferation on day 120 post-BMT in contrast to only 50% of patients with References a sibling donor and 30% of the patients with an unrelated donor transplant in our study. As reported, the reconsti- The reconstitution of HCMV-specific T cell proliferation 4 Reusser P, Riddell S, Meyers J, Greenberg P. Cytotoxic Twas found to be independent of the HCMV serostatus of lymphocyte response to cytomegalovirus after human allogthe donor in a small patient population (Table 2) cific immune reconstitution post-transplant. 7,9 Therefore,
